Key result
Rivaroxaban was associated with a similar risk of VTE recurrence and bleeding compared to dalteparin in patients with lung cancer (adjusted HR 1.176; 95% CI 0.595-2.324; p=0.641).
Why the study?
Although direct oral anticoagulant use has increased for cancer-associated VTE, their efficacy and safety specifically in lung cancer patients remain unclear.
Does rivaroxaban improve the composite of VTE recurrence and bleeding compared to dalteparin in patients with primary lung cancer and VTE?
Population
204 patients with primary lung cancer prescribed anticoagulation for VTE
Comparison
Rivaroxaban vs dalteparin
Design
Single-center retrospective study
Authors
Loading...
Supports rivaroxaban as potential alternative in lung cancer VTE; leaves open need for randomized confirmation.
Cohort (n=204)
No
Does rivaroxaban improve the composite of VTE recurrence and bleeding compared to dalteparin in patients with primary lung cancer and VTE?
Hazard Ratio: 1.176 (95% CI 0.595–2.324)
Absolute Event Rate: 29% vs 16.4%
p-value: p=0.641
Rivaroxaban demonstrated a similar safety and efficacy profile to dalteparin for the treatment of VTE in patients with primary lung cancer, suggesting it is a viable alternative.
Lee et al. (2019) conducted a cohort in Venous thromboembolism in primary lung cancer (n=204). Rivaroxaban vs. Dalteparin was evaluated on Composite event including VTE recurrence and major or clinically relevant nonmajor bleeding (HR 1.176, 95% CI 0.595-2.324, p=0.641). Rivaroxaban was associated with a similar risk of VTE recurrence and bleeding compared to dalteparin in patients with lung cancer (adjusted HR 1.176; 95% CI 0.595-2.324; p=0.641).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: